These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 21392988

  • 1. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
    Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2492-6. PubMed ID: 21392988
    [Abstract] [Full Text] [Related]

  • 2. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL, Bowen SJ, Schweitzer BA, Madsen HM, McDonald J, Pelc MJ, Tenbrink RE, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5970-4. PubMed ID: 19765986
    [Abstract] [Full Text] [Related]

  • 3. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
    Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Walker MC, Schweitzer BA, Madsen HM, Tenbrink RE, McDonald J, Smith SE, Foltin S, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2011 Nov 01; 21(21):6538-44. PubMed ID: 21924614
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2011 Nov 01; 21(21):6545-53. PubMed ID: 21924613
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
    Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, Surowy C, El Kouhen OF, Muchmore SW, Brioni JD, Stewart AO.
    J Med Chem; 2009 Jan 08; 52(1):170-80. PubMed ID: 19072118
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
    Kono M, Matsumoto T, Kawamura T, Nishimura A, Kiyota Y, Oki H, Miyazaki J, Igaki S, Behnke CA, Shimojo M, Kori M.
    Bioorg Med Chem; 2013 Jan 01; 21(1):28-41. PubMed ID: 23218778
    [Abstract] [Full Text] [Related]

  • 7. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM, Jones WM, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Brown SM, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2014 Feb 01; 24(3):737-41. PubMed ID: 24433863
    [Abstract] [Full Text] [Related]

  • 8. Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.
    Tichenor MS, Keith JM, Jones WM, Pierce JM, Merit J, Hawryluk N, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Wilson SJ, Wennerholm ML, Woestenborghs F, Beerens D, Luo L, Brown SM, Boeck MD, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7357-62. PubMed ID: 23141911
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
    Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J, Webb M, Karbarz MJ, Brown S, Wilson S, Scott B, Tham CS, Luo L, Palmer J, Wennerholm M, Chaplan S, Breitenbucher JG.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4838-43. PubMed ID: 18693015
    [Abstract] [Full Text] [Related]

  • 11. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC, Ding FX, Wang S, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Chen X, Zhang B, Tata JR, Berger JP, Colletti SL.
    Bioorg Med Chem Lett; 2009 Jul 01; 19(13):3398-404. PubMed ID: 19481932
    [Abstract] [Full Text] [Related]

  • 12. 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies.
    Käsnänen H, Myllymäki MJ, Minkkilä A, Kataja AO, Saario SM, Nevalainen T, Koskinen AM, Poso A.
    ChemMedChem; 2010 Feb 01; 5(2):213-31. PubMed ID: 20024981
    [Abstract] [Full Text] [Related]

  • 13. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
    Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6793-6. PubMed ID: 19850474
    [Abstract] [Full Text] [Related]

  • 14. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
    Roughley SD, Browne H, Macias AT, Benwell K, Brooks T, D'Alessandro J, Daniels Z, Dugdale S, Francis G, Gibbons B, Hart T, Haymes T, Kennett G, Lightowler S, Matassova N, Mansell H, Merrett A, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Simmonite H, Tan K, Walls SB, Wong M.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):901-6. PubMed ID: 22209458
    [Abstract] [Full Text] [Related]

  • 15. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S, Simone CD, Dallavalle S, Fezza F, Nannei R, Battista N, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, Cabri W, Penco S, Merlini L, Maccarrone M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4406-11. PubMed ID: 20591666
    [Abstract] [Full Text] [Related]

  • 16. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
    Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, Francis G, Gibbons B, Haymes T, Kennett G, Lightowler S, Mansell H, Matassova N, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Walls S, Wong M, Roughley S.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4241-4. PubMed ID: 19515560
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
    Kono M, Matsumoto T, Imaeda T, Kawamura T, Fujimoto S, Kosugi Y, Odani T, Shimizu Y, Matsui H, Shimojo M, Kori M.
    Bioorg Med Chem; 2014 Feb 15; 22(4):1468-78. PubMed ID: 24440478
    [Abstract] [Full Text] [Related]

  • 18. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH).
    Timmons A, Seierstad M, Apodaca R, Epperson M, Pippel D, Brown S, Chang L, Scott B, Webb M, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2109-13. PubMed ID: 18289847
    [Abstract] [Full Text] [Related]

  • 19. Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling.
    Lodola A, Capoferri L, Rivara S, Chudyk E, Sirirak J, Dyguda-Kazimierowicz E, Andrzej Sokalski W, Mileni M, Tarzia G, Piomelli D, Mor M, Mulholland AJ.
    Chem Commun (Camb); 2011 Mar 07; 47(9):2517-9. PubMed ID: 21240393
    [Abstract] [Full Text] [Related]

  • 20. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
    Forster L, Ludwig J, Kaptur M, Bovens S, Elfringhoff AS, Holtfrerich A, Lehr M.
    Bioorg Med Chem; 2010 Jan 15; 18(2):945-52. PubMed ID: 20005725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.